Whatever happened to, “I like shiny things but I’d marry you with paper rings”? Well, Travis Kelce put a much fancier ring on the finger of Taylor Swift (see it here) and it wasn’t only an army of Swifties popping off on the news, but also the stocks of jewelers as traders bet that this big engagement will trigger a wave of fresh proposals.
President Donald Trump’s push to oust Federal Reserve Governor Lisa Cook from her position may have upset US bonds and the dollar, but it didn’t leave any mark on the stock market. The S&P 500 and Nasdaq 100 rose 0.4% while the Russell 2000 outperformed with a 0.8% advance on Tuesday.
Analysts are scrambling to increase their price targets for Nvidia ahead of its Q2 results, seemingly much more confident in the affirmation they’ll be getting on the longevity of the AI boom and Nvidia’s critical role in facilitating it. Usually they at least have the restraint until after Nvidia earnings blow them away.Â
Over the past month, the average price target for Nvidia among analysts polled by Bloomberg has increased by 7.7%, the fastest growth rate this year.Â
Even still, the chip designer arguably hasn’t gotten much credit for a recovery in its China business. Nvidia has talked a ton about the importance of accessing the Chinese AI market — especially after effectively getting locked out after export restrictions were enacted in mid-April.
The company has since regained the ability to send its H20 chips to the world’s second-largest economy in exchange for sending 15% of revenues generated from those sales to the US government.
Already, those forgone sales have caused full-year revenues to be $10.5 billion lower than they otherwise would have, per Nvidia’s management, but it doesn’t seem like the company is benefiting vis-à -vis the Street’s view from this Chinese shift yet.
“We believe Nvidia earnings on deck is another positive catalyst for tech stocks that will further remind investors this is still only the bottom of the 2nd inning in the 9 inning game around building out the AI Revolution over the coming years to enterprises/consumers globally,” Wedbush Securities analyst Dan Ives wrote. “We continue to believe from our Asia field checks that demand to supply is 10:1 for Nvidia’s golden chips.”
For years, they’ve been working on a real-world problem that still eludes Big Pharma. And now they may have one of the most exciting biologics in development.
They are the biotech disruptor, Cytonics. After successfully treating 10,000+ osteoarthritis patients with their first-generation OA therapy, Cytonics is pioneering a next-gen treatment: CYT-108. A genetically-engineered variant of the naturally-occurring Alpha-2-Macroglobulin protein, CYT-108 could become one of the first disease-modifying drugs for OA.
CYT-108 recently completed FDA Phase 1 clinical trials — but there’s more. Recent research suggests that CYT-108's "super A2M" activity may prove to be potent as a melanoma therapy. With a provisional U.S. patent filed to expand the drug into oncology, Cytonics is rapidly evolving into the next potential biotech breakthrough.
🚨Don’t let the Cytonics opportunity pass you by. Invest in the future of biotech at $3/share before the round closes tonight.1
The minimum investment is $501.
The chorus of voices urging Apple to make a major AI acquisition to rectify its lagging position among its peers is getting louder, and it appears that Apple is at least listening.
Apple executives have discussed acquiring either OpenAI rival Mistral AI (which has a $10 billion valuation) or AI-powered search engine Perplexity (with a $20 billion valuation), The Information reported — but they have yet to make a move.
Despite being relatively early to the digital voice assistant game, Siri was not in fact the killer app of AI as originally hoped, with large language models actually appearing to be the kingmaker of the AI era.Â
Apple Intelligence, Cupertino’s homegrown effort, has had a bad time. Just last week, Apple’s stock popped on the news that it was potentially going to crawl on hands and knees to rival Google by using its Gemini AI to power Siri.Â
The iPhone maker has a lot of reasons to hesitate (which The Information covers in depth), including a history of only small acquisitions, not wanting to overpay, and fears of culture clashes.
When some of your most devoted analysts and stakeholders are practically begging to avoid having a “BlackBerry moment” in AI, the question becomes less “what is the correct valuation of an AI company to acquire” and more “how much money can Apple afford to shell out to silence doubters saying it’s about to miss the moment.” With $164 billion cash on hand as of March, the answer is probably lots.
Thanks to the $7,500 tax credit expiring at the end of September, customers who want a new EV are rushing to Tesla dealerships to capitalize on it. In combination with the steep discounts Tesla is offering — it makes sense for the company to get ahead of the federal tax credit sunset, too — the automaker is, for the first time in a while, seeing demand for its vehicles outpace supply.
Cytonics is choosing to answer to real people. Cytonics is focused on a years-long fight: developing a disease-modifying therapy for osteoarthritis (OA).
They’ve already treated 10,000+ patients with their first-generation biologic therapy for OA — and now, their breakthrough drug CYT-108 is undergoing FDA human clinical trials. If successful, this may offer regenerative effects to osteoarthritis joint tissues.
Right now, Cytonics is still open to everyday investors at $3/share — but only until tonight.1
The minimum investment is $501.
VF Corp. and Canada Goose climbed on Baird upgrades as fall shopping season kicks off
Eli Lilly rose after reporting encouraging trial results for its next-generation weight-loss pill
Chinese EV maker Nio accelerated after a JPMorgan upgrade to “overweight” from “neutral”
Constellation Brands, parent company of Modelo, slipped after Bank of America analysts downgraded it
AMD is partnering with IBM to develop “quantum-centric supercomputing”
Interactive Brokers is joining the S&P 500; Talen Energy is taking its place in the S&P MidCap 400
Pantera Capital is entering the digital treasury game with a $1.25 billion fundraise to buy solana
Meanwhile, Trump Media is partnering with Crypto.com with a $6.4 billion backing to build a new cronos-focused digital asset treasury firm
Cytonics just filed a U.S. provisional patent to expand its novel osteoarthritis biopharmaceutical, CYT-108, into melanoma. This dual-indication potential could put Cytonics on track for a major breakthrough — today’s the last day to invest at $3/share.1
Employment has declined 13% among entry-level workers in the fields most exposed to AI.
Earnings expected from Nvidia, Kohl’s, CrowdStrike, Snowflake, HP, Five Below, The J.M. Smucker Co., Williams-Sonoma, Abercrombie & Fitch, and Urban Outfitters
1 The minimum investment is $501 (167 units). This is a paid advertisement for Cytonics Regulation A+ Offering. Please read the offering circular and related risks on the Cytonics StartEngine page.
Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities.